New “atlas” charts how antibodies attack COVID-19 Spike variants
A new “atlas” has been created in the US that charts how 152 different antibodies attack the SARS-CoV-2 Spike protein.
A team of researchers at the Brigham and Women’s Hospital, US, have created a new “atlas” that shows how 152 antibodies attack the SARS-CoV-2 Spike (S) protein as it has evolved since 2020. The study also highlighted ones that are able to neutralise newer SARS-CoV-2 strains while identifying regions of the S protein that have become more resistant to attack. According to the team, this approach could help to inform strategies for broadly protective COVID-19 booster vaccines.
“Emerging data shows that vaccines still confer some protections from new SARS-CoV-2 variants, and our study shows how that works from an antibody standpoint,” said corresponding author Duane Wesemann. “This data can help us think about what the best kind of booster vaccine might be by studying how the repertoire of human antibodies recognises the S protein.”
The team examined the antibody-producing memory B cells of 19 patients who were infected with SARS-CoV-2 in March of 2020, before the emergence of new variants. They then studied how these antibodies bind to S protein models of the B.1.1.7 (Alpha), B.1351 (Beta) and P.1 (Gamma) variants of SARS-CoV-2. The authors confirmed that the hundreds of antibodies they studied largely bind to seven major “footprints” on the S protein. Moreover, while many of these antibodies competed to bind to the same regions of the early version of the SARS-CoV-2 S protein, some of them lost their potency against newer strains. Meanwhile, others emerged as broadly responsive neutralisers.
“Making different antibodies that compete for one region of the virus allows the immune system to be more flexible,” Wesemann added. “Otherwise-redundant recognition by antibodies targeting the same footprint of one version of the virus confers recognition depth of the same footprint on variants, and some antibodies maintain high neutralisation potency against all the variants. Now that we can identify the antibodies that are more broadly reactive to all of the variants, we can think about how to elicit them more strongly in a vaccine.”
The study was published in Cell.